Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Nov 27, 2022; 14(11): 1219-1229
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1219
Table 1 Comparative analysis of clinicopathological factors between patients with resected cancer of the second portion of the duodenum and ampullary carcinoma
Variable
Comparison
DC-II (n = 27), %
AC (n = 80)
P value
SexMale15 (55.6)49 (61.3)0.65
Female12 (44.4)31 (38.7)
AgeMedian (range)69 (41-85)64 (37-84)0.35
Preoperative BMI (kg/m2)Median (range)22.1 (16.9-27.3)21.7 (15.8-31.3)0.59
Preoperative mGPS01747-
1518-
2514-
017 (63.0)47 (58.8)0.82
1-210 (37.0)32 (40.0)
Preoperative biliary drainageNo21 (77.8)44 (55.0)0.042
Yes6 (22.2)36 (45.0)
Preoperative symptomsAbsent8 (29.6)31 (38.7)0.49
Present19 (70.4)49 (61.3)
Digestive symptomsAbsent13 (48.1)60 (75.0)0.0158
Present14 (51.9)20 (25.0)
Anemia or tarry stoolAbsent23 (85.2)77 (96.3)0.06
Present4 (14.8)3 (3.7)
Preoperative CA19-9 (U/mL)Normal19 (70.4)56 (70.0)1
Elevated8 (29.6)24 (30.0)
Preoperative CEA (ng/mL)Normal25 (92.6)66 (82.5)0.35
Elevated2 (7.4)13 (16.3)
SurgeryPD1238-
SSPPD1435-
PpPD17-
Operation time (min)Median (range) 451 (287-837)446.5 (266-736)0.44
Intraoperative blood loss volume (mL)Median (range)685 (80-4110)652 (150-9015)0.48
Gross appearanceProtruding type8 (29.6)59 (73.8)< 0.0001
Ulcerative-type19 (70.4)21 (26.2)
Histological gradePap13-
Well1042-
Mod1331-
Por14-
Muc20-
Pap/well11 (40.7)45 (56.3)0.19
Mod/por/muc16 (59.3)35 (43.7)
Tumor diameter (mm)Median (range)35 (14-65)18 (5-84)< 0.0001
T category1Tis523-
T1 (1a, 1b)5 (4, 1)9-
T2128-
T3516-
T4114-
T0–T211 (40.7)60 (75.0)0.0019
T3–T416 (59.3)20 (25.0)
N factorN01658-
N1522-
N26x-
Lymph node metastasisAbsent16 (59.3)58 (72.5)0.23
Present11 (40.7)22 (27.5)
Number of lymph nodes with metastasisMedian (range)0 (0–6)0 (0–12)0.13
M factorM024780.1
M132-
Stage 0522-
I (A, B)629 (11, 18)-
II A24-
II B319-
III (A, B)8 (5, 3)4-
IV32-
Lymphatic invasion 01550-
1412-
2715-
312-
X01-
015 (55.6)50 (62.5)0.5
1-312 (44.4)29 (36.3)
Venous invasion02069-
158-
222-
300-
X01-
020 (74.1)69 (86.3)0.13
1-37 (25.9)10 (12.5)
Postoperative complication (≥ CD III)No18 (66.7)42 (52.5)0.26
Yes9 (33.3)38 (47.5)
Adjuvant chemotherapyNo19 (70.4)55 (68.8)1
Yes 8 (29.6)25 (31.2)
Table 2 Comparison of the sites and the frequency of lymph node metastasis between the patients with cancer of the second portion of the duodenum and ampullary carcinoma
Variable
Comparison
DC-II (n = 27), %
AC (n = 80), %
P value
N-Pyapresent3(11.1)0 (0)0.0186
absent23 (85.2)73 (100)
N-Hepresent5 (18.5)4 (5)0.0432
absent22 (81.5)76 (95)
N-SPpresent7 (25.9)14 (17.5)0.40
absent20 (74.1)66 (82.5)
N-IPpresent3 (11.1)10(12.5) 1.00
absent24 (88.9)70 (87.5)
N-SMpresent2 (7.4)5 (6.2)1.00
absent25 (92.6)75 (93.8)
Table 3 Analysis of initial recurrent sites in patients with cancer of the second portion of the duodenum and ampullary carcinoma
Initial recurrent site
DC-II (n = 10), %
AC (n = 28), %
P value
Liver2 (20.0)6 (21.4)1.00
Lungs3 (30.0)6 (21.4)0.67
Distant lymph nodes 5 (50.0)10 (35.7)0.47
Peritoneal dissemination1 (10.0)3 (10.7)1.00
Local 0 (0)5 (17.9)0.29
Others1 (10.0)2 (7.1)1.00